An update from Cyclacel Pharmaceuticals ( (CYCC) ) is now available.
On May 6, 2025, Cyclacel Pharmaceuticals entered into a share exchange agreement with FITTERS Diversified Berhad to acquire its subsidiary, Fitters Sdn. Bhd., making it a wholly-owned subsidiary of Cyclacel. This transaction involves exchanging 100% of Fitters’ shares for 19.99% of Cyclacel’s common stock. The agreement, aimed at accelerating growth and enhancing stockholder value, requires approval from both companies’ stockholders and is expected to close by August 31, 2025. Post-transaction, Cyclacel will be renamed Bio Green Med Solution, Inc., and its shares will continue to be listed on the Nasdaq Capital Market.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology. The company is engaged in creating a diversified biopharmaceutical business with a pipeline of novel drug candidates targeting oncology and hematology indications.
Average Trading Volume: 2,517,731
Technical Sentiment Signal: Strong Sell
Current Market Cap: $95.76M
See more insights into CYCC stock on TipRanks’ Stock Analysis page.